The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer

Authors:
Vervoort SJ, Welsh SA, Devlin JR, Barbieri E, Knight DA, Offley S, Bjelosevic S, Costacurta M, Todorovski I, Kearney CJ, Sandow JJ, Fan Z, Blyth B, McLeod V, Vissers JHA, Pavic K, Martin BP, Gregory G, Demosthenous E, Zethoven M, Kong IY, Hawkins ED, Hogg SJ, Kelly MJ, Newbold A, Simpson KJ, Kauko O, Harvey KF, Ohlmeyer M, Westermarck J, Gray N, Gardini A, Johnstone RW
In:
Source: Cell
Publication Date: (2021)
Issue: 184(12): 3143-3162
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Basic Research
Drug Discovery
Cells used in publication:
HeLa
Species: human
Tissue Origin: cervix
THP-1
Species: human
Tissue Origin: blood
Platform:
4D-Nucleofector® X-Unit
Experiment

V5-PPP2R1A knock-in THP-1 cells
5 x 10^5 THP-1 cells were resuspended in 20 µL nucleofection solution (16.4µL SG nucleofector solution + 3.6µL supplement 1) from the SG Cell Line 4D-NucleofectorTM X kit (Lonza, V4XC-3032). 300 pmol PPP2R1A sgRNA (Synthego, Key Resources Table) was incubated with 100pmol Alt-R S.p. HiFi Cas9 Nuclease V3 (Integrated DNA Technologies, 1081061) at room temperature for 20 minutes prior to the addition of 566ng mCherry-P2A-V5-PPP2R1A donor template DNA (Integrated DNA Technologies, Key Resources Table) on ice (6mL total volume). THP-1 cells in SG buffer were mixed with the sgRNA/Cas9/template complex and transferred to a 16- well nucleocuvette strip. Nucleofection was performed using the FF-100 program of the Amaxa 4D Nucleofector X Unit (Lonza, AAF- 1002X) and cells were incubated at 37°C for 10 minutes post-nucleofection before addition of culture media. Following expansion, mCherry cells were FACS-selected using a BD FACSAriaTM Fusion sorter.

Generation of THP-1 CDK9AS/AS cells

sgRNAs targeting CDK9 (300 pmol; Key Resources Table) were incubated for 20 minutes at room temperature with 100pmol Alt-R SpCas9 nuclease (Integrated DNA Technologies, 1074182) prior to the addition of 100pmol of the CDK9 Phe-103-Ala dsDNA HDR template (Key Resources Table; final volume - 5 mL). The ribonucleoprotein complex was added to 5x10^6 THP-1 cells resuspended in 20 µL Nucleofector solution (16.4 µL SG nucleofector solution + 3.6 µL supplement 1) from the SG Cell Line 4D-NucleofectorTM Kit (Lonza, V4XC-3032). Cells were transferred to a 16-well NucleocuvetteTM strip and electroporated using the Amaxa 4D-Nucleofector TM X Unit (program FF-100, AAF-1002X). Electroporated cells were expanded in THP-1 culture media prior to isolation of single cell clones in 96-well culture plates using the Becton Dickinson Fusion FACS sorter.

Competitive Proliferation and Cell Death Assays

For HeLa, MM1.S, BJ-T and HS5 competition assays, cells stably expressing either the FUCas9Cherry or FUCas9CFP vector were electroporated with Alt-R S.p. HiFi Cas9 Nuclease V3 and INTS6-A targeting sgRNA or sgSCR (Synthego, Key Resources Table) respectively. 100pmol Alt-R S.p. HiFi Cas9 Nuclease V3 and 300pmol synthetic guide RNA were pre-incubated with sterile, nuclease-free water (snRNP reaction; 5 µL volume) at room-temperature for 20 minutes. 0.5 x10^6 cells were resuspended in 16.4 µL electroporation buffer plus 3.6 µL supplement (see below), mixed with the snRNP reaction, transferred to a 16-well NucleocuvetteTM strip and electroporated using the Amaxa 4D-NucleofectorTM X Unit (AAF-1002X). HeLa cells were prepared using SE buffer (Lonza V4XC-1012) and the CN-114 program, MM1.S cells were prepared using SG buffer (Lonza, V4XC-3032) and the FF-100 program, BJ-T and HS5 primary cells were prepared using P3 Primary Cell buffer (Lonza V4XP-3032) and the DS-138 program. 

Abstract

Gene expression by RNA polymerase II (RNAPII) is tightly controlled by cyclin-dependent kinases (CDKs) at discrete checkpoints during the transcription cycle. The pausing checkpoint following transcription initiation is primarily controlled by CDK9. We discovered that CDK9-mediated, RNAPII-driven transcription is functionally opposed by a protein phosphatase 2A (PP2A) complex that is recruited to transcription sites by the Integrator complex subunit INTS6. PP2A dynamically antagonizes phosphorylation of key CDK9 substrates including DSIF and RNAPII-CTD. Loss of INTS6 results in resistance to tumor cell death mediated by CDK9 inhibition, decreased turnover of CDK9 phospho-substrates, and amplification of acute oncogenic transcriptional responses. Pharmacological PP2A activation synergizes with CDK9 inhibition to kill both leukemic and solid tumor cells, providing therapeutic benefit in vivo. These data demonstrate that fine control of gene expression relies on the balance between kinase and phosphatase activity throughout the transcription cycle, a process dysregulated in cancer that can be exploited therapeutically.